These Analysts Lower Their Forecasts On AdaptHealth Following Weak Sales

Core Insights - AdaptHealth Corp. reported third-quarter sales of $805.86 million, missing the analyst consensus estimate of $809.30 million [1] - The company revised its FY24 net revenue guidance from a range of $3.255 billion - $3.315 billion to $3.220 billion - $3.260 billion [2] - Following the earnings announcement, AdaptHealth shares gained 8.4%, trading at $9.95 [2] Analyst Ratings and Price Targets - Baird analyst Eric Coldwell maintained an Outperform rating but lowered the price target from $16 to $14 [3] - Canaccord Genuity analyst Richard Close maintained a Buy rating and cut the price target from $14 to $13 [3] - UBS analyst Whit Mayo maintained a Buy rating and lowered the price target from $13 to $12 [3] - The consensus price target for AdaptHealth is $13.48 based on ratings from 10 analysts, with a high of $30 and a low of $6.5 [4] - The average price target from the most recent ratings implies a 31.58% upside for AdaptHealth Corp [4]